6533b85efe1ef96bd12c09dc
RESEARCH PRODUCT
Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions
Magali HaissaguerreBruno VergèsFrançoise Borson-chazotFrédéric AlbarelSarra SmatiC. CortetBenjamin BouilletPhilippe CaronChristine Do CaoDelphine DruiPhilippe ChansonFrédéric IllouzFrederic CastinettiE. MerlenPerrine BuffierEmmanuelle KuhnSégolène HescotBertrand CariouVéronique RaverotOlivier ChabreClaire BrietNajiba LahlouF. ArchambeaudJérôme Bertheratsubject
Oncologymedicine.medical_specialtyConsensusEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAntineoplastic Agents030209 endocrinology & metabolism[SDV.CAN]Life Sciences [q-bio]/CancerEndocrine System Diseases03 medical and health sciences0302 clinical medicineEndocrinologyDysthyroidismNeoplasmsInternal medicineAnimalsHumansMedicineEndocrine systemHypophysitisAdverse effectMTOR inhibitorsTyrosine kinase inhibitorsAdrenal failurebusiness.industryDiabetesGeneral MedicineImmunotherapy[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismDiscovery and development of mTOR inhibitors3. Good healthDyslipidemiaAnticancer treatment030220 oncology & carcinogenesisAdrenal failureImmunotherapybusinessdescription
IF 0.795 (2017); International audience; The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-10-18 |